title: Prediction of tumor control in patients with cervical cancer: analysis of combined volume and dynamic enhancement pattern by MR imaging.
abstract: OBJECTIVE
  Quantitative analysis of either tumor volume or dynamic enhancement pattern using MR imaging has been reported as useful in the prediction of response to radiation therapy in cancer of the cervix. Because data for both analyses can be obtained in a single MR examination, the purpose of this study was to evaluate whether combining both analyses can further improve the efficacy of using MR imaging to predict tumor control after radiation therapy.
  
  
  METHODS
  Twenty patients with bulky carcinomas of the cervix, stages bulky IB (n = 2), IIB (n = 6), IIIA (n = 1), IIIB (n = 9), IVA (n = 1), and recurrent (n = 1), were studied. Initial tumor volumes were calculated by outlining the area of tumor in each slice on T2-weighted images and multiplying by the slice profile. Two dynamic contrast-enhanced MR studies were obtained in each patient immediately before the start of radiation therapy and after 20-22 Gy in 2 weeks of radiation therapy. Dynamic enhancement imaging was performed at 3-sec intervals in the sagittal plane for 120 sec after rapid (9 ml/sec) i.v. injection of MR contrast agent (0.1 mmol/kg of gadoteridol) using a power injector. Time and signal intensity curves reflecting the relative signal intensity of contrast enhancement in the tumor region were generated, and the relative signal intensity of the tumor region during the early plateau phase was calculated. Median follow-up was 25 months (range, 11-35 months).
  
  
  RESULTS
  The combined analysis did not improve the prediction rate of local recurrence in small-sized tumors, which responded well to radiation therapy regardless of their dynamic enhancement pattern. However, the combined analysis did improve the prediction rate of local recurrence in intermediate- and large-sized tumors (75% and 80%, respectively) over assessment by either volume analysis (33% and 60%, respectively) or dynamic enhancement pattern analysis (64% and 64%, respectively). The combined analysis was most useful in intermediate-sized tumors (40-99 cm3; 33% recurrence), significantly improving differentiation between high-risk (80% recurrence) and low-risk 10% recurrence) patients (p = .010).
  
  
  CONCLUSIONS
  Our preliminary results suggest that the combined data of both tumor morphologic (volume) and microcirculatory (dynamic enhancement pattern) parameters allow more accurate prediction of local failure in patients with advanced cervical cancer than does each individual parameter alone. Combined data appear to have the greatest potential in patients with intermediate-sized tumors, who constitute most patients (60%) and remain a challenge for outcome prediction and management.
authors.affiliation: Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City 52242, USA.
authors.forename: N A
authors.initials: NA
authors.lastname: Mayr
authors.forename: W T
authors.initials: WT
authors.lastname: Yuh
authors.forename: J
authors.initials: J
authors.lastname: Zheng
authors.forename: J C
authors.initials: JC
authors.lastname: Ehrhardt
authors.forename: V A
authors.initials: VA
authors.lastname: Magnotta
authors.forename: J I
authors.initials: JI
authors.lastname: Sorosky
authors.forename: R E
authors.initials: RE
authors.lastname: Pelsang
authors.forename: L W
authors.initials: LW
authors.lastname: Oberley
authors.forename: D H
authors.initials: DH
authors.lastname: Hussey
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D002294:Carcinoma, Squamous Cell / Q000473:pathology* / Q000532:radiotherapy*; D002584:Cervix Uteri / Q000473:pathology; D003287:Contrast Media; D005260:Female; D005682:Gadolinium; D006571:Heterocyclic Compounds; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009942:Organometallic Compounds; D011237:Predictive Value of Tests; D011882:Radiotherapy, High-Energy; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000532:radiotherapy*
chemical_list: D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; D005682:Gadolinium